Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

About this update from Ovid Therapeutics Inc.

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. “Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation,” said Meg Alexander, President and Chief Executive Officer, Ovid Therapeutics. “Her pioneering work in ion channel biology has fundamentally advanced our understanding of disease biology and enabled the development of targeted clinical-stage therapies. Anna’s scientific leadership, strategic insight, and experience across academia, biotech, and company-building will be invaluable as we continue to translate our portfolio of KCC2 direct activators for a range of potential neurological and neuropsychiatric conditions and advance our epilepsy programs through multiple proof-of-concept trials.” “Ovid’s focus on developing precise, mechanism-based therapies for neurological conditions aligns deeply with my mission of translating foundational science into meaningful treatments for patients,” said Dr. Greka. “The company’s innovative approach and commitment to addressing significant unmet need make this an exciting time to join the Board. My career has centered on advancing a deep understanding of disease biology and translating those insights into differentiated therapeutic strategies with clear clinical potential. I look forward to joining the team and applying my experience and capabilities in leading collaborative efforts between academic scientists, clinicians, and industry partners to accelerate therapeutic development for the benefit of patients.” Dr. Greka is a globally recognized physician-scientist, academic leader, and biotech entrepreneur with over 25 years of experience advancing foundational biological discoveries into clinical-stage assets. She currently leads the Ladders to Cures (L2C) Scientific Accelerator, an organization focused on translating fundamental discoveries into therapies across multiple disease indications and modalities. She is a Core Institute Member at the Broad Institute of MIT and Harvard and serves on its Executive Leadership Team, helping guide s...

View stock analysis, news, and events for Ovid Therapeutics Inc.